Andrew Smith, MD
Allergy & Immunology · Sandy, UTNPI 1164468955
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $438,259 of the $648,839 with a category attached, or 67.5%. 50 manufacturers reported payments, led by AstraZeneca at 33.9% of the total. Among allergy & immunology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,548 payments — averaging $419.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$220K
- Takeda Pharmaceuticals U.S.A., Inc.$146K
- Pharming Healthcare, Inc.$78K
- Biocryst US Sales Co., LLC$70K
- Optinose US, Inc.$39K
- Shire North American Group Inc$27K
- plus $69K from 44 others
Across 151 payments — averaging $4493.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$240K
- Novartis$166K
- Teva Pharmaceuticals USA, Inc.$73K
- GSK$52K
- Biocryst Pharmaceuticals, Inc.$47K
- Astrazeneca AB$38K
- plus $62K from 4 others
What the payments were for
- Consulting fees$118,03418%
- Speaking & faculty fees$438,25968%
- Travel & lodging$62,39010%
- Food & beverage$29,9515%
- Education$2050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$648,839 in reported general payments places this provider in the 95th percentile of 30 allergy & immunology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IcatibantIcatibant Acetate | 11 | $115,515 |
| XolairOmalizumab | 26 | $70,151 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $69,297 |
| TezspireTezepelumab-Ekko | 13 | $55,875 |
| Dupixent PenDupilumab | 13 | $44,987 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $34,074 |
| Cromolyn Sodium | 39 | $22,167 |
| Spiriva RespimatTiotropium Bromide | 29 | $17,396 |
| DuleraMometasone/Formoterol | 17 | $11,814 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,838 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $6,534 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,234 |
| Epinephrine | 23 | $4,789 |
| Mometasone Furoate | 47 | $4,749 |
| QnaslBeclomethasone Dipropionate | 11 | $4,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $219,931 | $94,16272 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $784 | $84,051118 claims |
| Genentech, Inc.Xolair | $89 | $70,15126 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $14,468 | $22,63040 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $112 | $22,16739 claims |
| MerckDulera | $15 | $11,81417 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $4,78923 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $2,786 | $4,46711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 allergy & immunology providers in Utah.
Other allergy & immunology in Sandy
- Huyen-Tran NguyenSandy$82
- Jonathan OlsenDraper$60K
- Jaron AbbottProvo$22K
- Tara SarinMurray$20K
- Richard HendershotPark City$16K
- Loida Viera HutchinsMurray$8K
- Stephen BodenBountiful$7K
- Alexander NicholsonWest Jordan$7K
- Joshua BurkhardtSalem$6K
- Evan MathesonProvo$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.